Research and Markets: Primary Sclerosing Cholangitis Pipeline Review, H2 2015 - 6 Companies & 6 Drug Profiles
September 04 2015 - 8:26AM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/c4vmrl/primary) has
announced the addition of the "Primary Sclerosing Cholangitis -
Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the
therapeutic development for Primary Sclerosing Cholangitis,
complete with comparative analysis at various stages, therapeutics
assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along with latest updates,
and featured news and press releases. It also reviews key players
involved in the therapeutic development for Primary Sclerosing
Cholangitis and special features on late-stage and discontinued
projects.
The report enhances decision making capabilities and helps to
create effective counter strategies to gain competitive advantage.
It strengthens R&D pipelines by identifying new targets and
MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Biotie Therapies Corp.
- ChemoCentryx, Inc.
- Dr. Falk Pharma GmbH
- Gilead Sciences, Inc.
- Intercept Pharmaceuticals, Inc.
- Shire Plc
Drug Profiles
- BTT-1023
- CCX-507
- norursodeoxycholic acid
- obeticholic acid
- SHP-625
- simtuzumab
For more information visit
http://www.researchandmarkets.com/research/c4vmrl/primary
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150904005291/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Pharmaceuticals